CABIO(SH:688089) Zheng Quan Zhi Xing·2025-07-02 16:24Core Viewpoint - The legal opinion issued by Beijing Zhonglun Law Firm confirms that the differentiated dividend distribution plan proposed by Jia Biyou Biotechnology (Wuhan) Co., Ltd. complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [6][11][12]. Group 1: Differentiated Dividend Distribution - The differentiated dividend distribution is based on the company's 2024 profit distribution plan, which proposes a cash dividend of 0.20094 RMB per share, totaling approximately 33.66 million RMB, calculated on a base of 167,519,992 shares after deducting repurchased shares [9][10]. - The company has repurchased 789,128 shares, and the total share capital is 168,309,120 shares, which affects the calculation of the dividend distribution [10][11]. - The company will not conduct capital reserve transfers or issue bonus shares, with any remaining undistributed profits carried forward to future years [11]. Group 2: Legal Compliance and Verification - The law firm conducted thorough verification of the documents and facts provided by the company, ensuring the accuracy and completeness of the legal opinion [4][5]. - The legal opinion is based on existing laws, regulations, and the company's articles of association, confirming that the differentiated dividend distribution does not violate any legal provisions [6][12]. - The law firm emphasizes that the opinion is solely for the purpose of the differentiated dividend distribution and cannot be used for any other purpose without consent [5][12].